Kerala Ayurveda Ltd
Incorporated in 1945, Kerala Ayurveda Ltd is engaged In Ayurvedlc services and products[1]
- Market Cap ₹ 214 Cr.
- Current Price ₹ 165
- High / Low ₹ 625 / 161
- Stock P/E
- Book Value ₹ 19.9
- Dividend Yield 0.00 %
- ROCE -10.8 %
- ROE -47.6 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 2.47% over last quarter.
Cons
- Stock is trading at 8.27 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.75% over past five years.
- Promoter holding is low: 35.6%
- Company has a low return on equity of -20.3% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 84.0 to 108 days.
- Promoter holding has decreased over last 3 years: -25.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 28 | 33 | 40 | 44 | 46 | 54 | 43 | 56 | 63 | 73 | 78 | 80 | |
| 23 | 25 | 28 | 35 | 38 | 43 | 51 | 43 | 48 | 58 | 69 | 91 | 104 | |
| Operating Profit | 3 | 3 | 4 | 5 | 6 | 3 | 3 | 0 | 8 | 5 | 4 | -13 | -24 |
| OPM % | 11% | 12% | 12% | 12% | 13% | 6% | 6% | 0% | 14% | 8% | 5% | -16% | -29% |
| 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 3 | 5 | 18 | |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 6 | 6 | 5 | 5 | 4 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 |
| Profit before tax | 1 | 2 | 2 | 3 | 3 | 2 | 1 | -7 | 1 | 2 | -0 | -13 | -18 |
| Tax % | 31% | 30% | 31% | 32% | 32% | 31% | 28% | -25% | 28% | -22% | -138% | 2% | |
| 1 | 1 | 2 | 2 | 2 | 1 | 1 | -5 | 1 | 3 | 0 | -14 | -19 | |
| EPS in Rs | 0.98 | 1.05 | 1.64 | 2.08 | 2.18 | 1.14 | 0.83 | -4.69 | 0.84 | 2.74 | 0.04 | -11.45 | -15.50 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 8% |
| 3 Years: | 12% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -954% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 26% |
| 3 Years: | 25% |
| 1 Year: | -53% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -20% |
| 3 Years: | -20% |
| Last Year: | -48% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 |
| Reserves | 3 | 3 | 5 | 4 | 7 | 3 | 4 | -1 | 1 | 4 | 21 | 13 | 12 |
| 60 | 64 | 64 | 52 | 70 | 56 | 58 | 66 | 61 | 64 | 64 | 56 | 68 | |
| 5 | 5 | 5 | 9 | 13 | 17 | 21 | 20 | 19 | 21 | 20 | 38 | 38 | |
| Total Liabilities | 79 | 84 | 84 | 76 | 100 | 87 | 94 | 96 | 92 | 99 | 116 | 119 | 130 |
| 18 | 17 | 16 | 16 | 16 | 17 | 17 | 26 | 28 | 30 | 28 | 31 | 32 | |
| CWIP | 0 | 0 | 0 | 6 | 9 | 10 | 12 | 2 | 2 | 0 | 0 | 1 | 1 |
| Investments | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 9 | 9 | 9 |
| 50 | 56 | 57 | 42 | 63 | 49 | 53 | 56 | 50 | 57 | 79 | 77 | 89 | |
| Total Assets | 79 | 84 | 84 | 76 | 100 | 87 | 94 | 96 | 92 | 99 | 116 | 119 | 130 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | 0 | 2 | 2 | -11 | 9 | 5 | -1 | 9 | 9 | -5 | 2 | |
| -2 | -2 | -1 | -2 | -2 | -2 | -4 | -2 | 1 | -5 | -1 | -6 | |
| 1 | 3 | -2 | 1 | 16 | -11 | 0 | 2 | -11 | -2 | 21 | -12 | |
| Net Cash Flow | -1 | 2 | 0 | -0 | 3 | -4 | 1 | -1 | -1 | 2 | 15 | -16 |
| Free Cash Flow | -1 | 0 | 2 | 0 | -14 | 7 | 2 | -2 | 6 | 8 | -6 | -5 |
| CFO/OP | -4% | 9% | 61% | 32% | -192% | 332% | 152% | -433% | 113% | 185% | -126% | -18% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 56 | 59 | 57 | 60 | 69 | 62 | 83 | 68 | 70 | 74 | 108 |
| Inventory Days | 299 | 283 | 234 | 369 | 380 | 327 | 307 | 238 | 213 | 200 | 183 | 176 |
| Days Payable | 103 | 104 | 58 | 78 | 123 | 115 | 151 | 126 | 122 | 124 | 115 | 90 |
| Cash Conversion Cycle | 257 | 235 | 236 | 348 | 318 | 282 | 218 | 195 | 159 | 146 | 142 | 194 |
| Working Capital Days | -108 | -94 | -69 | -193 | -6 | 54 | 22 | -26 | -157 | -37 | -202 | -53 |
| ROCE % | 3% | 4% | 5% | 6% | 7% | 3% | 4% | -1% | 10% | 6% | 6% | -11% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Count |
|
||||||||||
| Service Revenue Weightage (as % of Turnover) % |
|||||||||||
| Herbarium Plant Varieties Count |
|||||||||||
| Number of Certified Students / Alumni (USA Academy) Count |
|||||||||||
| Number of Major Distribution Depots Count |
|||||||||||
| Number of SKUs Count |
|||||||||||
| R&D Expenditure as % of Turnover % |
|||||||||||
| India E-commerce Revenue Growth % |
|||||||||||
| Number of Treatment Centers and Wellness Clinics Count |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % |
|||||||||||
Documents
Announcements
-
Closure of Trading Window
26 Mar - Trading window closed March 31, 2026 until 48 hours after audited FY2026 results announcement.
-
Board Meeting Outcome for Outcome Of Board Meeting
25 Mar - Board approved private placement of 4,000 NCDs totaling Rs40 crore; 12% p.a., 24-month moratorium, 32 quarterly installments.
-
Board Meeting Intimation for The Proposal For Fund Raising By Way Of Issue Of Unlisted, Secured, Redeemable Non-Convertible Debentures For A Value Upto Rs. 40 Crores To Be Held On 25 March 2026.
21 Mar - Board on 25 Mar 2026 to consider issuing secured NCDs up to Rs.40 crore; trading window closed.
-
Announcement under Regulation 30 (LODR)-Allotment
21 Mar - 21 Mar 2026: Allotment of 9,34,887 shares; Rs20.66Cr loan conversion; Rs99,999,887.13 share-swap; Ayurvedagram wholly-owned.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
14 Mar - EGM Mar 14, 2026: approved 630,000 preferential shares to Katra; 304,887 swap shares; ESOP-2023 amended.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2018TranscriptAI SummaryPPT
Business Overview:[1]
Company manufactures Ayurveda products and deals in Ayurveda Research, Academies, Clinics, Hospitals, Ayurvedic Wellness Resorts and Services, cultivation of Ayurveda herbs, and maintaining a herbarium of medicinal plants